Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials.
about
Rofecoxib for osteoarthritisGastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humansRole of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug usersAssessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tractPrevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: the OITA-GF study 2.Accounting for the increase in NSAID expenditure: substitution or leakage?Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritisRelative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugsIncidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind studyGastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations.Non-steroidal anti-inflammatory drugs: who should receive prophylaxis?Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.Superior digestive tract side effects after prolonged treatment with NSAIDs in patients with osteoarthritis.Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin.Testing for interaction in studies of noninferiority.Effect of cyclooxygenase-2 inhibition on human Helicobacter pylori gastritis: mechanisms underlying gastrointestinal safety and implications for cancer chemoprevention.Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?The CINOD, AZD3582, exhibits an improved gastrointestinal safety profile compared with naproxen in healthy volunteers.COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study.Biphasic effects of H. pylori infection on low-dose aspirin-induced gastropathy depending on the gastric acid secretion level.Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors.Correlation between Helicobacter pylori infection and low-dose aspirin use on damage of the upper gastrointestinal tract.
P2860
Q24244871-31631949-0D90-48B0-9C69-1E8B5FA7CEF9Q24669542-5E4602B3-CBEE-4BAE-BCE9-D2609742529EQ28182449-8963E010-3BE8-40C8-B9D8-8516AD3AC785Q28196933-33A3477C-5FDF-4D38-BD81-7059FB56DFBAQ34636856-4870D7AC-02C7-42C6-BF0B-B5CFC4D714D3Q34768089-8E2F5EF7-6763-42FC-9C2E-8C2E3657ACB1Q35083808-BEECA201-BF0F-4931-A3FB-876482723ABFQ35195182-C446F172-244A-4A46-8A0C-9FBF2428E659Q35555299-7AA7F5B8-C653-4371-AC51-9B9192FAE515Q35594966-5F173F70-1A97-4213-A38B-3C0AF80A2226Q35595723-85C08B45-473C-495E-8D42-4F8289E7941CQ35873867-35903ADA-D90B-467F-B7CD-8254FE0E0184Q35873871-AF3AFB08-4319-4B2B-9375-CA33C181D11CQ35875744-5CB5BDB0-36D5-4C9F-9802-FE85853F8A49Q36309948-33F6E2C6-7252-4E98-AFCF-944532A34864Q43266149-56FDAB9F-9592-42D6-8285-650EFC0A5714Q44361084-A33E3542-6B5E-4E42-A283-5E00816FDBA7Q44488912-7264A5BE-8320-4162-8F89-5B1A85A7E366Q44808671-9745BFEE-99E4-494E-8F30-D920C53ABC78Q44808681-B2462DD4-B555-4B55-997C-102760528317Q44813874-7D936D95-C37B-4DC9-BB44-6E821F039C6FQ45265821-9D640E7E-300D-4A8E-94C9-CD00BF6DD0B1Q46447268-A7557552-5118-44FE-BA07-714917073EEDQ51346297-6A348A81-7A1F-4AD2-A01D-12B0981CE993
P2860
Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Influence of risk factors on e ...... randomized controlled trials.
@en
Influence of risk factors on e ...... randomized controlled trials.
@nl
type
label
Influence of risk factors on e ...... randomized controlled trials.
@en
Influence of risk factors on e ...... randomized controlled trials.
@nl
prefLabel
Influence of risk factors on e ...... randomized controlled trials.
@en
Influence of risk factors on e ...... randomized controlled trials.
@nl
P2093
P2860
P1476
Influence of risk factors on e ...... randomized controlled trials.
@en
P2093
C J Hawkey
E Mortensen
J A Bolognese
Rofecoxib Osteoarthritis Endoscopy Multinational Study Group
S E Harper
P2860
P304
P356
10.1046/J.1365-2036.2001.01007.X
P407
P577
2001-10-01T00:00:00Z